Kardatuxan (Rivaroxaban)

Kardatuxan, a direct factor Xa inhibitor, is employed in several thrombo‑embolic conditions.

• Non‑valvular atrial fibrillation: reduces risk of stroke and systemic embolism.
• Deep vein thrombosis (DVT): treats acute clot formation in the leg veins.
• Pulmonary embolism (PE): manages clot obstruction in the pulmonary arteries.
• Recurrent DVT/PE: prevents further thrombotic episodes after initial treatment.
• Post‑operative thromboprophylaxis: lowers clot risk after hip or knee replacement surgery.

• Rivaroxaban selectively inhibits factor Xa in the coagulation cascade, blocking the conversion of prothrombin to thrombin. By reducing thrombin generation, it decreases fibrin clot formation without requiring antithrombin activation, providing anticoagulation across the intrinsic and extrinsic pathways.

Rivaroxaban may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Bleeding: gums, nose, or easy bruising.
• Gastrointestinal upset: nausea, diarrhea, abdominal pain.
• Headache: mild to moderate intensity.
• Dizziness or vertigo.
• Rash or mild skin irritation.

Serious or Rare Side Effects

• Major hemorrhage: intracranial or gastrointestinal bleeding.
• Spinal or epidural hematoma, especially after neuraxial procedures.
• Severe liver injury: jaundice, elevated transaminases.
• Allergic reactions: anaphylaxis, angioedema.
• Thrombocytopenia: low platelet count leading to bleeding.

Before initiating therapy, several safety considerations are recommended.

• Renal impairment: assess kidney function and adjust dose if needed.
• Hepatic disease: use with caution in patients with moderate to severe liver dysfunction.
• Concomitant anticoagulants: avoid or closely monitor combined use due to heightened bleeding risk.
• Surgery or invasive procedures: discontinue appropriately before the procedure to reduce bleeding.
• Pregnancy and breastfeeding: safety not established; evaluate risks versus benefits.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Rivaroxaban interacts with several drug classes that can modify its anticoagulant effect.

Major Interactions (Avoid)

• Other anticoagulants (e.g., warfarin, heparin): markedly increased bleeding risk.
• Strong CYP3A4 and P‑glycoprotein inhibitors (e.g., ketoconazole, ritonavir): elevate plasma concentrations.
• Antiplatelet agents (e.g., clopidogrel, aspirin at high dose): synergistic bleeding potential.

Moderate Interactions (Monitor Closely)

• NSAIDs (e.g., ibuprofen, naproxen): may increase gastrointestinal bleeding.
• SSRIs or SNRIs (e.g., sertraline, venlafaxine): modest rise in bleeding tendency.
• Certain antifungals (e.g., fluconazole) and antibiotics (e.g., rifampin): may alter rivaroxaban levels.
• Herbal supplements containing St. John’s wort: can reduce drug exposure.